Clinical Trial

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2023-12-19; most recent amendment 2026-07-21.
Status change: Not Yet Recruiting → Recruiting 2024-02-09
Trial Details
NCT Number NCT06179069
Lead Sponsor Zai Lab (Shanghai) Co., Ltd.
Collaborators: Zai Lab (US) LLC
Conditions SCLC
Enrollment 339 participants
Start Date 2024-01-23
Primary Completion 2027-05-30 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-23